Grants and Contributions:
Title:
Development of tolerogenic lipid nanoparticle (LNP) formulation containing messenger ribonucleic acid (mRNA)
Agreement Number:
982040
Agreement Value:
$77,176.00
Agreement Date:
Oct 16, 2021 - Mar 15, 2022
Description:
Development of lipid nanoparticles (LNP) encasing mRNA for vaccines.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5G 4X4
Reference Number:
172-2021-2022-Q3-982040
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
824601991
Recipient Type:
For-profit organization
Recipient's Legal Name:
Integrated Nanotherapeutics Inc.
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710